{"id":"mcs-2","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, MCS-2 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. Its exact mechanism of action is still being studied in clinical trials.","oneSentence":"MCS-2 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:48.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01002664","phase":"PHASE3","title":"Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Health Ever Bio-Tech Co., Ltd.","startDate":"2010-05","conditions":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","enrollment":272},{"nctId":"NCT01002274","phase":"PHASE3","title":"Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Health Ever Bio-Tech Co., Ltd.","startDate":"2010-08","conditions":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","enrollment":180},{"nctId":"NCT01002417","phase":"PHASE2, PHASE3","title":"MCS in the Treatment of Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Health Ever Bio-Tech Co., Ltd.","startDate":"2010-07","conditions":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","enrollment":274},{"nctId":"NCT01002222","phase":"PHASE3","title":"Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)","status":"COMPLETED","sponsor":"Health Ever Bio-Tech Co., Ltd.","startDate":"2011-01","conditions":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","enrollment":200},{"nctId":"NCT01003171","phase":"PHASE1","title":"Pharmacokinetics of MCS in Healthy Volunteers","status":"UNKNOWN","sponsor":"Health Ever Bio-Tech Co., Ltd.","startDate":"2011-08","conditions":"Healthy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MUS"],"phase":"phase_3","status":"active","brandName":"MCS-2","genericName":"MCS-2","companyName":"Health Ever Bio-Tech Co., Ltd.","companyId":"health-ever-bio-tech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MCS-2 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}